Impact on blood safety of the last arboviruses outbreaks in French Polynesia (2012-2018).


Journal

Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine
ISSN: 1953-8022
Titre abrégé: Transfus Clin Biol
Pays: France
ID NLM: 9423846

Informations de publication

Date de publication:
Feb 2020
Historique:
received: 16 10 2019
accepted: 03 12 2019
pubmed: 1 1 2020
medline: 5 1 2021
entrez: 1 1 2020
Statut: ppublish

Résumé

Several successive arbovirus outbreaks have affected French Polynesia (FP) in the recent past years due to different dengue serotypes (DENV) present for several decades, Zika (ZIKV) (2013-2014) and chikungunya (CHIKV) (2014-2015) viruses with a potential impact on blood safety and blood supply due to the geographical isolation of these islands. This study reports an assessment of the impact of these outbreaks on blood products supply and infectious safety in FP and discuss the effectiveness of implemented preventive measures. To ensure the infectious safety of blood products during outbreaks, several measures have successively been introduced as the selection of donors suspected of infection, the nucleic acid testing (NAT) and the pathogen reduction of platelets and plasmas. The donor deferral rate increased by 6% between 2012 and 2014 without changes in the number of collected donations. NAT excluded five blood donations reactive for DENV RNA, 42 for ZIKV and 34 for CHIKV. As Zika screening could not been implemented before the third month of the outbreak, 36 blood products from ZIKV-infected donors were transfused to 26 recipients. However, no transfusion-transmitted arbovirus has been reported. The last past arboviruses outbreaks did not have a significant impact on blood supply in FP. The measures introduced to prevent arbovirus transmission by transfusion were able to maintain infectious safety for all blood products without impairing self-sufficiency.

Sections du résumé

BACKGROUND BACKGROUND
Several successive arbovirus outbreaks have affected French Polynesia (FP) in the recent past years due to different dengue serotypes (DENV) present for several decades, Zika (ZIKV) (2013-2014) and chikungunya (CHIKV) (2014-2015) viruses with a potential impact on blood safety and blood supply due to the geographical isolation of these islands. This study reports an assessment of the impact of these outbreaks on blood products supply and infectious safety in FP and discuss the effectiveness of implemented preventive measures.
METHODS METHODS
To ensure the infectious safety of blood products during outbreaks, several measures have successively been introduced as the selection of donors suspected of infection, the nucleic acid testing (NAT) and the pathogen reduction of platelets and plasmas.
RESULTS RESULTS
The donor deferral rate increased by 6% between 2012 and 2014 without changes in the number of collected donations. NAT excluded five blood donations reactive for DENV RNA, 42 for ZIKV and 34 for CHIKV. As Zika screening could not been implemented before the third month of the outbreak, 36 blood products from ZIKV-infected donors were transfused to 26 recipients. However, no transfusion-transmitted arbovirus has been reported.
CONCLUSION CONCLUSIONS
The last past arboviruses outbreaks did not have a significant impact on blood supply in FP. The measures introduced to prevent arbovirus transmission by transfusion were able to maintain infectious safety for all blood products without impairing self-sufficiency.

Identifiants

pubmed: 31889619
pii: S1246-7820(19)30464-1
doi: 10.1016/j.tracli.2019.12.001
pii:
doi:

Substances chimiques

Furocoumarins 0
Photosensitizing Agents 0
RNA, Viral 0
amotosalen K1LDZ0VBC0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

4-9

Informations de copyright

Copyright © 2019 Société française de transfusion sanguine (SFTS). Published by Elsevier Masson SAS. All rights reserved.

Auteurs

F Beau (F)

Centre de transfusion sanguine de Polynésie française, hôpital du Taaone, centre hospitalier de Polynésie française, Pirae, BP 4530, 98713 Papeete, Tahiti, French Polynesia. Electronic address: frederic.beau@cht.pf.

S Lastère (S)

Laboratoire de biologie, hôpital du Taaone, centre hospitalier de Polynésie française, Pirae, Tahiti, French Polynesia.

H-P Mallet (HP)

Centre de transfusion sanguine de Polynésie française, hôpital du Taaone, centre hospitalier de Polynésie française, Pirae, BP 4530, 98713 Papeete, Tahiti, French Polynesia.

S Mauguin (S)

Unité d'hémovigilance, hôpital du Taaone, centre hospitalier de Polynésie française, Pirae, Tahiti, French Polynesia.

J Broult (J)

Centre de transfusion sanguine de Polynésie française, hôpital du Taaone, centre hospitalier de Polynésie française, Pirae, BP 4530, 98713 Papeete, Tahiti, French Polynesia.

S Laperche (S)

Institut national de la transfusion sanguine, département des agents transmissibles par le sang, centre national de référence risques infectieux transfusionnels, Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH